Heart Failure

A systematic review and meta-analysis detail the unadjusted odds of developing chemotherapy-related cardiotoxicity among patients who are Black or of African ancestry relative to their White counterparts.

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

An analysis of data from patients in the DELIVER and DAPA-HF trials in the Americas provides an overview of the benefits of dapagliflozin in Black patients relative to White patients.

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

Released on March 21, the new scientific statement suggests supervised exercise training is safe and may offer substantial improvement in exercise capacity and quality of life, even more than medications, for many patients with heart failure.

At ACC 2023, results from the RAPID-HF trial reported atrial pacing was ineffective at improving exercise capacity in patients with HFpEF and chronotropic incompetence.

Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.

Implantation of a pacemaker to enhance exercise heart rate did not improve exercise capacity, symptoms, or exercise cardiac output in patients with HFpEF and chronotropic incompetence in the RAPID-HF trial.

Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.

Clyde Yancy, MD, offers insight into his keynote address and the importance of both recognizing and addressing inequities within heart failure management.

In a Q&A at ACC 2023, Drs. Alexandra Murphy and Birgit Vogel of Mount Sinai discuss sex-specific predictors of MACE and the need for individualization of care to achieve equity in cardiovascular health.

Results from the STOP-CA trial suggest patients taking atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo.

A new meta-analysis of 9 randomized trials suggests restricting dietary sodium intake to levels below 2.3 grams per day may increase the risk of death in patients with heart failure.

Cytokinetics announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials for the agent while focusing on the development of aficamten.

Ahead of the PDUFA date for omecamtiv mecarbil, HCPLive reached out to a trio of heart failure specialists to learn about their opinion of the agent based on clinical trial data, their reaction to the November 2022 AdComm vote, and whether they believe the agent warrants approval from the US FDA.

Using the GWTG-HF registry, new data elucidates the differences in the likelihood of being prescribed GDMT among patients hospitalized with heart failure in rural compared to urban settings.

Results of the CaReMe HF Study, which pooled registry data from 11 countries spanning 2018-2021, suggest the prevalence of heart failure could be as high as 2% of the general population and also offers insight into trends in uptake of GDMT among these patients.

Don't Miss a Beat hosts are joined by Alexandre Mebazaa, MD, PhD, lead investigator of the STRONG-HF trial, to discuss the inspiration for the trial, its design, and important takeaways for those looking to implement a similar strategy of rapid, in-hospital uptitration of GDMT in heart failure at their own practice.

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.

An analysis of data from the Rochester Epidemiology Project suggests those with breast cancer or lymphoma who received treatment with anthracycline therapy experienced a more than doubling in risk of heart failure compared to controls without cancer.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

Using data from more than 2 million US adults with nonsurgical hospitalizations, a new study from the Mayo Clinic is sounding the alarm on the increased cardiovascular risk associated with developing sepsis.

New data from the AHA 2023 Statistical Update suggest more people died from cardiovascular-related causes in 2020 than in any year since 2003.

An analysis of the Jackson Heart Study reports economic food insecurity as a risk factor for incident CHD and incident HFrEF, independent of socioeconomic measures and traditional CV risk factors.

Rurality was associated with an increased risk of HF among women and Black men, which persisted after adjustment for cardiovascular risk factors and socioeconomic status.